These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35551858)

  • 1. CFTR dysfunction and targeted therapies: A vision from non-cystic fibrosis bronchiectasis and COPD.
    Martinez-Garcia MA; Sierra-Párraga JM; Quintana E; López-Campos JL
    J Cyst Fibros; 2022 Sep; 21(5):741-744. PubMed ID: 35551858
    [No Abstract]   [Full Text] [Related]  

  • 2. CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.
    Patel SD; Bono TR; Rowe SM; Solomon GM
    Eur Respir Rev; 2020 Jun; 29(156):. PubMed ID: 32554756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.
    Fernandez Fernandez E; De Santi C; De Rose V; Greene CM
    Expert Rev Respir Med; 2018 Jun; 12(6):483-492. PubMed ID: 29750581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.
    Ziedalski TM; Kao PN; Henig NR; Jacobs SS; Ruoss SJ
    Chest; 2006 Oct; 130(4):995-1002. PubMed ID: 17035430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CFTR gene mutations in adults with disseminated bronchiectasis.
    Girodon E; Cazeneuve C; Lebargy F; Chinet T; Costes B; Ghanem N; Martin J; Lemay S; Scheid P; Housset B; Bignon J; Goossens M
    Eur J Hum Genet; 1997; 5(3):149-55. PubMed ID: 9272738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The relationship between cystic fibrosis and bronchiectasis and its research implications in Chinese].
    Li HP; He GJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Sep; 27(9):627-9. PubMed ID: 15498278
    [No Abstract]   [Full Text] [Related]  

  • 8. Potential systemic effects of acquired CFTR dysfunction in COPD.
    Miravitlles M; Criner GJ; Mall MA; Rowe SM; Vogelmeier CF; Hederer B; Schoenberger M; Altman P
    Respir Med; 2024 Jan; 221():107499. PubMed ID: 38104786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis.
    Elborn JS
    Lancet; 2016 Nov; 388(10059):2519-2531. PubMed ID: 27140670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
    Cantin AM
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S150-5. PubMed ID: 27115950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy.
    Farley H; Poole S; Chapman S; Flight W
    Postgrad Med J; 2022 May; 98(1159):341-345. PubMed ID: 33452147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease.
    Shi J; Li H; Yuan C; Luo M; Wei J; Liu X
    Oxid Med Cell Longev; 2018; 2018():6567578. PubMed ID: 29849907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update in cystic fibrosis 2013.
    Jain M; Goss CH
    Am J Respir Crit Care Med; 2014 May; 189(10):1181-6. PubMed ID: 24832742
    [No Abstract]   [Full Text] [Related]  

  • 17. CFTR: cystic fibrosis and beyond.
    Mall MA; Hartl D
    Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His.
    Keenan K; Dupuis A; Griffin K; Castellani C; Tullis E; Gonska T
    J Cyst Fibros; 2019 Mar; 18(2):265-270. PubMed ID: 30279124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical sinusitis in adults must lead to looking for cystic fibrosis and primary ciliary dyskinesia.
    Coste A; Girodon E; Louis S; Prulière-Escabasse V; Goossens M; Peynègre R; Escudier E
    Laryngoscope; 2004 May; 114(5):839-43. PubMed ID: 15126740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.
    Paredes Aller S; Quittner AL; Salathe MA; Schmid A
    Expert Rev Respir Med; 2018 Sep; 12(9):769-782. PubMed ID: 30025482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.